Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | AMEX | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 22 | -0.50 Decreased by -2.40 K% | -0.02 Decreased by -120.00 K% |
| Aug 9, 22 | -0.01 Increased by +50.00% | -0.01 Decreased by -7.49 K% |
| May 16, 22 | -0.02 Increased by 0.00% | -0.02 |
| Mar 29, 22 | -0.04 Decreased by -300.00% | -0.02 Decreased by -5.00 K% |
| Nov 10, 21 | -0.02 Increased by +93.33% | -0.02 |
| Aug 4, 21 | -0.02 Increased by 0.00% | -0.02 |
| May 5, 21 | -0.02 Increased by +50.00% | -0.02 |
| Mar 3, 21 | -0.01 Increased by 0.00% | -0.01 Decreased by -7.49 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -3.67 M Increased by +34.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -2.10 M Increased by +66.18% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -6.49 M Decreased by -78.91% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -2.10 M Increased by +40.89% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -5.64 M Decreased by -53.78% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -6.22 M Decreased by -34.81% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -3.63 M Decreased by -7.72% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -3.56 M Decreased by -30.21% | Decreased by N/A% Decreased by N/A% |
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.